EICHOR
● Active Not Recruiting
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasms, Castration-Resistant · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib combination therapies (Combinations 1 and 2) and b) to determine the relative bioavailability of niraparib and abiraterone acetate (AA) in combination (Combination 3) in participants with metastatic castration-resistant prostate cancer (mCRPC).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (50)
| Urological Associates of Southern Arizona, P.C. | Tucson, Arizona, United States | — |
| The Urology Center of Colorado | Denver, Colorado, United States | — |
| Mayo Clinic - Division Of Hematology/oncology | Jacksonville, Florida, United States | — |
| First Urology, PSC | Jeffersonville, Indiana, United States | — |
| Chesapeake Urology Research Associates | Towson, Maryland, United States | — |
| Michigan Institute of Urology | Troy, Michigan, United States | — |
| New York Oncology Hematology | Albany, New York, United States | — |
| Memorial Sloan Kettering Cancer Center 1 | Harrison, New York, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| Thomas Jefferson University | Philadelphia, Pennsylvania, United States | — |
| University of Pittsburgh Medical Center (UPMC) | Pittsburgh, Pennsylvania, United States | — |
| MUSC-Hollings Cancer Center | Charleston, South Carolina, United States | — |
+ 38 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03431350